In situ hybridisation was used to determine whether the expression of two different isoforms of amyloid precursor protein (APP) mRNA (APP714 and APP751) could be selectively modified following treatment with excitatory amino acid agonists (quisqualic acid or ibotenic acid) when administered directly into the rat hippocampus either alone or following pre-treatment with a specific excitatory amino acid antagonist (2,3-dihydro-6-nitro-7-sulphamoyl-benzo(F)quinoxaline, NBQX; D-2-amino-5-phosphonovaleric acid, AP5; or 5,7-dichlorokynurenic acid, 5,7-DCKA). It was found that APP mRNA isoform expression was differentially influenced according to treatment. Central administration of an excitatory amino acid agonist may therefore be useful for investigating mechanisms controlling APP expression in vivo.
|Number of pages||8|
|Journal||Pharmacology Reviews and Communications|
|Publication status||Published - 1 Jan 1999|